

Trastuzumab deruxtecan [1826843-81-5]

#Cat: NB-64-24343-1mg	Size: 1mg
#Cat: NB-64-24343-5mg	Size: 5mg
#Cat: NB-64-24343-10mg	Size: 10mg
#Cat: NB-64-24343-50mg	Size: 50mg
#Cat: NB-64-24343-25mg	Size: 25mg
#Cat: NB-64-24343-3mg	Size: 3mg

Chemical Properties

Cas No:	1826843-81-5
Formula:	
Molecular weight:	
Appearance:	no data available
Storage:	store at low temperature store at -20°C

Biological Description

Description	Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
Targets(IC₅₀)	Antibody-Drug Conjugates (ADCs)
In vitro	<p>Methods: HER2-positive KPL-4 cells were treated with Trastuzumab deruxtecan (T-DXd) (1 pM-10 nM, 5 days) and cell viability was calculated.</p> <p>Results: Trastuzumab deruxtecan can inhibit the growth of HER2-positive KPL-4 cells with an IC₅₀ value of 109.7 pM. [2]</p> <p>Methods: Trastuzumab deruxtecan (10 nM, 5 days) was used to treat cocultured HER2-positive KPL-4 cells and HER2-negative MDA-MB-468 cells, and the number of viable cells was measured to determine whether it induced bystander killing.</p> <p>Results: Trastuzumab deruxtecan killed both KPL-4 and MDA-MB-468 cells. [2]</p>
In vivo	<p>Methods: Trastuzumab deruxtecan (T-DXd) (10 mg/kg, intravenous injection) was used to treat EMT6-hHER2 tumor-bearing mice, and the changes in tumors in the mice were observed.</p> <p>Results: Trastuzumab deruxtecan significantly inhibited tumor growth in EMT6-hHER2 tumor-bearing mice 18 days after treatment. [1]</p>

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use